CCNB2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P10797(CCNB2 Antibody) at dilution 1/10. (Original magnification: ×200)    

  
  

**Background of CCNB2 Antibody**

CCNB2 (Cyclin B2) is a regulatory protein involved in cell cycle progression, specifically during the transition from the G2 phase to mitosis. As a member of the cyclin family, CCNB2 binds and activates cyclin-dependent kinase 1 (CDK1), forming a complex essential for initiating mitotic entry, spindle assembly, and chromosome segregation. Dysregulation of CCNB2 has been linked to genomic instability, cancer development, and poor prognosis in various malignancies, as its overexpression can drive uncontrolled cell proliferation.

CCNB2 antibodies are immunological tools designed to detect and quantify CCNB2 protein levels in cells or tissues. These antibodies are widely used in research to study cell cycle dynamics, tumor biology, and mechanisms of chemotherapeutic resistance. Common applications include Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. Specificity and validation are critical, as cross-reactivity with other cyclins (e.g., CCNB1) can occur.

Recent studies highlight CCNB2's potential as a biomarker for cancer diagnosis or therapeutic targeting. For instance, elevated CCNB2 expression correlates with advanced tumor stages in breast, lung, and ovarian cancers. Additionally, CCNB2 antibodies aid in exploring its non-mitotic roles, such as in DNA damage repair and apoptosis. Continued research using these antibodies may uncover novel pathways for precision oncology interventions.